EX-99.SECTION 19(A) 4 tm2030671d1_ex99section19a.htm EXHIBIT 99.SECTION19(A)

 

Exhibit 99.Section 19(a)

 

EXHIBIT 4: SECTION 19(a) NOTICE TO FUND’S SHAREHOLDERS

 

TEKLA LIFE SCIENCES INVESTORS

 

Notification of Sources of Distribution

 

Distribution Paid Date: June 30, 2020

 

Distribution Amount Per Common Share: $0.34

 

The following table sets forth the estimated amounts of the current distribution, paid June 30, 2020, and the cumulative distributions paid this fiscal year-to-date from the following sources: net investment income, net realized short-term capital gains, net realized long-term capital gains, and return of capital or other capital source.

 

   Current
Distribution		   Percentage
Breakdown
of Current
Distribution		   Total Cumulative
Distributions for the
Fiscal Year to Date1		   Percentage
Breakdown of the
Total Cumulative
Distributions for the
Fiscal Year to Date1		 
Net Investment Income  $0.0000    0%  $0.0000    0%
Net Realized ST Cap Gains  $0.2118    62%  $0.2118    20%
Net Realized LT Cap Gains  $0.1282    38%  $0.8482    80%
Return of Capital or Other Capital Source  $0.0000    0%  $0.0000    0%
TOTAL (per common share):  $0.3400    100%  $1.0600    100%

 

The table below includes information relating to the Fund’s performance based on its NAV for certain periods.

 

Average annual total return at NAV for the period from April 30, 2015 through April 30, 2020   3.40%
Annualized current distribution rate expressed as a percentage of NAV as of April 30, 2020   7.02%
Cumulative total return at NAV for the fiscal year, through April 30, 20202   23.00%
Cumulative fiscal year-to-date distribution rate expressed as a percentage of NAV as of April 30, 20201   5.47%

 

You should not draw any conclusions about the Fund’s investment performance from the amount of this distribution or from the terms of the Fund’s managed distribution policy.

 

The composition of this and subsequent distribution may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sale of securities is $163,698,946, of which $144,824,655 represents net unrealized appreciation of portfolio securities.

 

The amounts and sources of distributions reported in this 19(a) Notice are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.

 

1 The Fund’s current fiscal year began on October 1, 2019.

2 Cumulative total return at NAV is the percentage change in the Fund’s NAV and includes all distributions and assumes the reinvestment of those distributions for the period of September 30, 2019 through April 30, 2020.

 

Tekla Life Sciences Investors

CUSIP: 87911K100

www.teklacap.com

 

Tekla Capital Management LLC

100 Federal Street, 19th Floor

Boston, Massachusetts 02110

 

617-772-8500

Fax: 617-772-8577

 

 

 

 

TEKLA LIFE SCIENCES INVESTORS

 

Notification of Sources of Distribution

 

Distribution Paid Date: September 30, 2020

 

Distribution Amount Per Common Share: $0.41

 

The following table sets forth the estimated amounts of the current distribution, paid September 30, 2020, and the cumulative distributions paid this fiscal year-to-date from the following sources: net investment income, net realized short-term capital gains, net realized long-term capital gains and return of capital or other capital source.

 
   Current
Distribution		   Percentage
Breakdown
of Current
Distribution		   Total Cumulative
Distributions for the
Fiscal Year to Date1		   Percentage
Breakdown of the
Total Cumulative
Distributions for the
Fiscal Year to Date1		 
Net Investment Income  $0.0000    0%  $0.0000    0%
Net Realized ST Cap Gains  $0.0000    0%  $0.2118    14%
Net Realized LT Cap Gains  $0.4100    100%  $1.2582    86%
Return of Capital or Other Capital Source  $0.0000    0%  $0.0000    0%
TOTAL (per common share):  $0.4100    100%  $1.4700    100%

 

The table below includes information relating to the Fund’s performance based on its NAV for certain periods.

 

Average annual total return at NAV for the period from July 31, 2015 through July 31, 2020   2.16%
Annualized current distribution rate expressed as a percentage of NAV as of July 31, 2020   8.01%
Cumulative total return at NAV for the fiscal year, through July 31, 20202   32.41%
Cumulative fiscal year-to-date distribution rate expressed as a percentage of NAV as of July 31, 20201   7.18%

 

You should not draw any conclusions about the Fund’s investment performance from the amount of this distribution or from the terms of the Fund’s managed distribution policy.

 

The composition of this and subsequent distribution may vary from quarter to quarter because it may be materially impacted by future realized gains and losses on securities. The aggregate of the net unrealized appreciation of portfolio securities and net realized gains on sale of securities is $152,963,475, of which $119,328,491 represents net unrealized appreciation of portfolio securities.

 

The amounts and sources of distributions reported in this 19(a) Notice are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.

 

1 The Fund’s current fiscal year began on October 1, 2019.

2 Cumulative total return at NAV is the percentage change in the Fund’s NAV and includes all distributions and assumes the reinvestment of those distributions for the period of September 30, 2019 through July 31, 2020.

 

Tekla Life Sciences Investors

CUSIP: 87911K100

www.teklacap.com

 

Tekla Capital Management LLC

100 Federal Street, 19th Floor

Boston, Massachusetts 02110

 

617-772-8500

Fax: 617-772-8577